Showing 5021-5030 of 9749 results for "".
- Triple-Combo Gel Reduces Acne Lesions, Scarring, and PIH Over 6 Months: Studyhttps://practicaldermatology.com/news/study-triple-combo-gel-reduces-acne-lesions-scarring-and-pih-over-6-months/2474438/Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) was associated with significant long-term efficacy and safety in the treatment of moderate acne and associated sequelae, results from a new 24-week open-label study indicate.
- SEEN Expands Pediatric Line with Fragrance-Free Baby Shampoo and Body Washhttps://practicaldermatology.com/news/seen-expands-pediatric-line-with-fragrance-free-baby-shampoo-and-body-wash/2474436/SEEN has announced the launch of SEEN Baby 2-in-1 Fragrance Free, a new ultra-gentle shampoo and body wash designed specifically for infants and young children with sensitive or eczema-prone skin, according to a news release from the manufacturer.
- Study Finds Gaps in Lichen Planus Screening and Treatment Among U.S. Dermatologistshttps://practicaldermatology.com/news/study-finds-gaps-in-lichen-planus-screening-and-treatment-among-us-dermatologists/2474421/A new cross-sectional study from George Washington University shows significant variability in how U.S. dermatologists diagnose and manage lichen planus, according to a news release. Surveying over 400 board-certified dermatol
- Study Shows Prognostic Value of 40-GEP in Advanced cSCChttps://practicaldermatology.com/news/study-shows-prognostic-value-of-40-gep-in-advanced-cscc/2474383/A new multi-institutional study indicates that a 40-gene expression profile (40-GEP) test with traditional staging enhances risk stratification for cutaneous squamous cell carcinoma (cSCC), even among patients already categorized as high- or very-high-risk using Na
- RILECSU Study: Rilzabrutinib Effective for Symptoms in Hard-to-Treat Urticariahttps://practicaldermatology.com/news/rilecsu-trial-rilzabrutinib-eases-symptoms-in-hard-to-treat-urticaria/2474350/Rilzabrutinib significantly reduced itch and hives in adults with antihistamine-refractory chronic spontaneous urticaria (CSU), according to new phase 2 trial results published in JAMA Dermatology.
- Study: Laser Therapy Shows Success in HS Management for Skin of Colorhttps://practicaldermatology.com/news/new-study-highlights-laser-therapy-success-in-hs-management-for-skin-of-color/2474344/Fractional ablative CO₂ laser therapy (AFCL) significantly improved hidradenitis suppurativa (HS) outcomes among patients with skin of color, according to a new retrospective study presented at the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual
- EARLY: Guselkumab Use Supported in PsO Patients With HBV, Cancer, or Heart Diseasehttps://practicaldermatology.com/news/early-guselkumab-use-supported-in-pso-patients-with-hbv-cancer-or-heart-disease/2474211/Guselkumab, an IL-23 inhibitor approved for moderate-to-severe psoriasis, showed long-term safety in patients with complex comorbidities—including chronic infections, prior malignancies, and cardiovascular disease—according to findings from the EARLY Study.
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://practicaldermatology.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk
- Survey Reveals Clinician Views on CHE's Impact on Quality of Lifehttps://practicaldermatology.com/news/Survey-Reveals-Clinician-Views-CHEs-Impact-Quality-Life/2474228/Ninety-five percent of US dermatology clinicians surveyed agreed moderate-to-severe chronic hand eczema (CHE) has a strong impact on patients’ work and home life, according to the second phase of a survey sponsored by LEO Pharma Inc., the company announced in a press release. The survey, w
- Increased Cost Diminishes Sunscreen Use: Reporthttps://practicaldermatology.com/news/cost-influences-sunscreen-use-raising-skin-cancer-risk-study-shows/2474206/Patients use less sunscreen when it’s more expensive, according to a brief report in the Journal of the American Academy of Dermatology. Researchers from the University of California, Sa